URGN Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
UroGen Pharma Ltd. had $110M of revenue in fiscal 2025, up 21.4% on the year before. Over five years, revenue changed +56.2% a year on average.
Last close Β· Oct 23, 2026
$34.49
1.9%Hi! I read UroGen Pharma Ltd.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+21.4%
Yes. Sales grew 21.4% last year.
Does it make a profit?
β139.8%
No. It lost money last year.
Does profit turn into cash?
β148.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· UroGen Pharma Ltd. had $110M of revenue in fiscal 2025, up 21.4% on the year before. Over five years, revenue changed +56.2% a year on average. Its operating margin was β113.7%, down 6.7Β pts: of every 100 in sales, about β114 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· UroGen Pharma Ltd. lost $153M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$163M in fiscal 2025, β148.2% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $4.8M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$4.8M
3 insiders
Of sales under plans
27%
$1.3M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 8, 2026 | Chris DegnanChief Financial Officer | Sold | 2,202 | $36.69 | $0.1M | Form 4 |
| Sep 8, 2026 | Jason Drew SmithGeneral Counsel | Sold | 1,519 | $42.54 | $0.1M | Form 4 |
| Sep 8, 2026 | Mark SchoenbergChief Medical Officer | Sold | 871 | $42.92 | $0.0M | Form 4 |
| Aug 20, 2026 | Mark SchoenbergChief Medical Officer | Sold | 60,677 | $47.05 | $2.9M | Form 4 |
| Jul 9, 2026 | Mark SchoenbergChief Medical Officer | Sold plan | 10,000 | $40.00 | $0.4M | Form 4 |
| Jun 22, 2026 | Mark SchoenbergChief Medical Officer | Sold plan | 10,000 | $35.01 | $0.4M | Form 4 |
| Jun 8, 2026 | Mark SchoenbergChief Medical Officer | Sold | 5,222 | $27.30 | $0.1M | Form 4 |
| May 8, 2026 | Mark SchoenbergChief Medical Officer | Sold plan | 10,000 | $30.00 | $0.3M | Form 4 |
| Feb 3, 2026 | Jason Drew SmithGeneral Counsel | Sold | 7,479 | $19.69 | $0.1M | Form 4 |
| Feb 3, 2026 | Mark SchoenbergChief Medical Officer | Sold | 7,373 | $19.69 | $0.1M | Form 4 |
| Nov 19, 2025 | Mark SchoenbergChief Medical Officer | Sold plan | 10,000 | $25.00 | $0.3M | Form 4 |
| Oct 8, 2025 | Chris DegnanChief Financial Officer | Sold | 2,203 | $16.85 | $0.0M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· UroGen Pharma Ltd. has $30.3M more cash than debt.
Cash, debt and the ratios that show how comfortably UroGen Pharma Ltd. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $89.1M | $100.0M | $151M | $283M | $160M |
| Debt incl. finance leases | $0.0M | $97.5M | $98.6M | $124M | $130M |
| Debt / equity | 0.0x | β | β | β | β |
| Current ratio | 5.1x | 5.4x | 5.4x | 6.0x | 4.0x |
| Quick ratio | 4.9x | 5.2x | 5.2x | 5.8x | 3.7x |
| Total assets | $120M | $136M | $178M | $286M | $200M |
| Total liabilities | $111M | $225M | $244M | $295M | $306M |
| Shareholders' equity | $8.4M | β$89.4M | β$65.2M | β$8.8M | β$105M |
| Net debt (β = net cash) | β$89.1M | β$2.4M | β$52.6M | β$159M | β$30.3M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· UroGen Pharma Ltd. passes 1 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 5 | 1 / 8 | 4 / 8 | 2 / 8 | 3 / 8 | 4 / 8 | 5 / 8 | 5 / 8 | 1 / 8 |
| Accruals ratio | β | β13.8% | β42.8% | β22.3% | β13.9% | β21.5% | β17.4% | β16.5% | β13.0% | 3.7% |
| Altman Z'' | β | 12.27 | 3.77 | 5.45 | β7.50 | β12.78 | β13.13 | β10.10 | β6.22 | β15.59 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $17.5M | $8.2M | $1.1M | $0.0M | $11.8M | $48.0M | $64.4M | $82.7M | $90.4M | $110M |
| Gross profit | $17.5M | $7.6M | β$0.7M | $0.0M | $10.8M | $42.9M | $56.7M | $73.4M | $81.5M | $97.3M |
| Research and development | β | $18.7M | $36.9M | $49.3M | $47.3M | $47.6M | $52.9M | $45.6M | $57.1M | $67.1M |
| Operating income | $0.8M | β$20.0M | β$77.2M | β$109M | β$127M | β$92.3M | β$79.0M | β$65.5M | β$96.8M | β$125M |
| Pretax income | β$1.9M | β$20.0M | β$75.5M | β$105M | β$125M | β$109M | β$108M | β$98.3M | β$124M | β$153M |
| Income tax | β | $0.0M | $0.1M | β | $3.4M | $1.4M | $1.8M | $3.9M | $2.8M | $0.1M |
| Net income | β$1.9M | β$20.0M | β$75.7M | β$105M | β$128M | β$111M | β$110M | β$102M | β$127M | β$153M |
| Net income to common | β$4.4M | β$20.8M | β$75.7M | β$105M | β$128M | β | β | β | β | β |
| Diluted EPS | β$1.91 | β$2.14 | β$4.80 | β$5.12 | β$5.90 | β$4.96 | β | β | β | β |
| Diluted shares | 0.00B | 0.01B | 0.02B | 0.02B | 0.02B | 0.02B | β | β | β | β |
| Cash flow | ||||||||||
| Cash from operations | $4.2M | β$9.6M | β$37.3M | β$71.0M | β$106M | β$84.9M | β$87.6M | β$76.4M | β$96.8M | β$162M |
| Capital expenditure | $0.7M | $0.3M | $0.6M | $0.3M | $1.2M | $0.8M | $0.3M | $0.2M | $0.3M | $0.3M |
| Free cash flow | $3.5M | β$9.8M | β$37.9M | β$71.3M | β$107M | β$85.6M | β$87.8M | β$76.6M | β$97.1M | β$163M |
| Depreciation and amortization | $0.2M | $0.2M | $0.4M | $0.3M | $0.4M | $0.8M | $0.9M | $0.8M | $0.3M | $0.3M |
| Stock-based compensation | $2.0M | $6.3M | $30.6M | $30.0M | $28.0M | $23.1M | $10.6M | $9.3M | $13.1M | $12.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | β | $73.0M | $101M | $147M | $102M | $89.1M | $100.0M | $151M | $283M | $160M |
| Total debt | β | β | β | β | β | $0.0M | $97.5M | $98.6M | $122M | $125M |
| Finance lease liabilities | β | β | β | β | β | β | β | β | $2.3M | $4.8M |
| Current assets | β | $74.5M | $102M | $149M | $116M | $114M | $129M | $169M | $276M | $186M |
| Current liabilities | β | $7.0M | $13.5M | $19.5M | $21.4M | $22.4M | $23.9M | $31.2M | $45.9M | $46.4M |
| Inventory | β | $0.3M | β | β | $2.0M | $4.8M | $4.3M | $5.7M | $9.2M | $16.5M |
| Property and equipment, net | β | $0.8M | $0.9M | $1.0M | $2.0M | $2.0M | $1.3M | $0.7M | $0.7M | $0.6M |
| Total assets | β | $75.6M | $104M | $202M | $122M | $120M | $136M | $178M | $286M | $200M |
| Total liabilities | β | $7.0M | $13.5M | $22.1M | $25.7M | $111M | $225M | $244M | $295M | $306M |
| Shareholders' equity | $16.3M | $68.5M | $90.1M | $180M | $96.4M | $8.4M | β$89.4M | β$65.2M | β$8.8M | β$105M |
| Margins | ||||||||||
| Gross margin | 99.8% | 92.6% | β59.8% | 100.0% | 91.4% | 89.3% | 88.1% | 88.7% | 90.2% | 88.7% |
| Operating margin | 4.6% | β244.5% | β6,842.2% | β608,211.1% | β1,074.2% | β192.1% | β122.8% | β79.2% | β107.1% | β113.7% |
| EBITDA margin | 5.7% | β242.1% | β6,806.7% | β606,544.4% | β1,070.6% | β190.4% | β121.4% | β78.3% | β106.7% | β113.5% |
| Net margin | β11.1% | β245.2% | β6,707.2% | β584,144.4% | β1,088.9% | β230.7% | β170.6% | β123.6% | β140.4% | β139.8% |
| FCF margin | 19.9% | β120.6% | β3,359.4% | β396,344.4% | β907.7% | β178.3% | β136.4% | β92.6% | β107.4% | β148.2% |
| Returns | ||||||||||
| Return on capital employed | β | β29.1% | β85.7% | β59.9% | β126.0% | β94.8% | β70.8% | β44.6% | β40.4% | β81.1% |
| Return on equity | β11.9% | β47.2% | β95.4% | β77.8% | β92.9% | β211.6% | β | β | β | β |
| Return on assets | β | β26.5% | β84.5% | β68.7% | β79.2% | β91.7% | β86.0% | β65.1% | β54.7% | β63.1% |
| Return on tangible equity | β27.0% | β30.4% | β84.0% | β58.3% | β133.3% | β1,317.2% | β | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | β53.5% | β86.2% | β98.4% | 65,450.0% | 307.2% | 34.0% | 28.5% | 9.3% | 21.4% |
| FCF growth | β | β381.6% | β | β | β | β | β | β | β | β |
| Share count change | β | 321.5% | 62.1% | 30.3% | 6.1% | 2.6% | β | β | β | β |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | β | 0.0x | β | β | β | β |
| Current ratio | β | 10.6x | 7.6x | 7.6x | 5.4x | 5.1x | 5.4x | 5.4x | 6.0x | 4.0x |
| Quick ratio | β | 10.5x | 7.6x | 7.6x | 5.3x | 4.9x | 5.2x | 5.2x | 5.8x | 3.7x |
| Capital allocation | ||||||||||
| Capex / revenue | 4.0% | 3.3% | 49.6% | 1,805.6% | 10.3% | 1.6% | 0.4% | 0.2% | 0.3% | 0.3% |
| Stock comp / revenue | 11.2% | 77.2% | 2,716.5% | 166,483.3% | 237.5% | 48.1% | 16.4% | 11.3% | 14.5% | 10.9% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | 1.0 | 4.0 | 2.0 | 3.0 | 4.0 | 5.0 | 5.0 | 1.0 |
| Altman Z'' | β | 12.3 | 3.8 | 5.5 | β7.5 | β12.8 | β13.1 | β10.1 | β6.2 | β15.6 |
| Accruals ratio | β | β13.8% | β42.8% | β22.3% | β13.9% | β21.5% | β17.4% | β16.5% | β13.0% | 3.7% |
Source: SEC EDGAR XBRL filings (CIK 0001668243). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
